Literature DB >> 23397688

Case reports: Death of active duty soldiers following ingestion of dietary supplements containing 1,3-dimethylamylamine (DMAA).

Michael J Eliason1, Amy Eichner, Anthony Cancio, Lori Bestervelt, Bruce D Adams, Patricia A Deuster.   

Abstract

Dietary supplements and their associated adverse events are not uncommon in the U.S. military, and selected dietary supplements have been associated with a number of nontraumatic deaths in service members. Specific ingredients and dietary supplement products in the civilian community are often associated with multiple adverse events and some have subsequently been removed from the marketplace; the most notable in the last decade is ephedra. We present case reports for two soldiers who were taking commercially available dietary supplements containing multiple ingredients to include the sympathomimetic, 1,3-dimethylamylamine (DMAA); both collapsed during physical exertion from cardiac arrest and ultimately died. A presentation of their clinical courses and a discussion of the history and pharmacology of dietary supplement ingredients, including DMAA, are provided. Our cases highlight concerns that DMAA in combination with other ingredients may be associated with significant consequences, reminiscent of previous adverse events from other sympathomimetic drugs previously removed from the market.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23397688     DOI: 10.7205/milmed-d-12-00265

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  16 in total

1.  Disinhibiting neurons in the dorsomedial hypothalamus delays the onset of exertional fatigue and exhaustion in rats exercising in a warm environment.

Authors:  Dmitry V Zaretsky; Hannah Kline; Maria V Zaretskaia; Mary Beth Brown; Pamela J Durant; Nathan J Alves; Daniel E Rusyniak
Journal:  Brain Res       Date:  2018-03-22       Impact factor: 3.252

2.  Abuse liability of the dietary supplement dimethylamylamine.

Authors:  Sean B Dolan; Michael B Gatch
Journal:  Drug Alcohol Depend       Date:  2014-11-25       Impact factor: 4.492

3.  The Role of Adverse Event Reporting in the FDA Response to a Multistate Outbreak of Liver Disease Associated with a Dietary Supplement.

Authors:  Karl C Klontz; Heidi J DeBeck; Pamela LeBlanc; Kathryn M Mogen; Beverly J Wolpert; Jonathan L Sabo; Monique Salter; Sharon L Seelman; Susan E Lance; Caitlin Monahan; David S Steigman; Kathleen Gensheimer
Journal:  Public Health Rep       Date:  2015 Sep-Oct       Impact factor: 2.792

4.  Identification of black market products and potential doping agents in Germany 2010-2013.

Authors:  Oliver Krug; Andreas Thomas; Katja Walpurgis; Thomas Piper; Gerd Sigmund; Wilhelm Schänzer; Tim Laussmann; Mario Thevis
Journal:  Eur J Clin Pharmacol       Date:  2014-08-30       Impact factor: 2.953

Review 5.  Adverse Effects of Nutraceuticals and Dietary Supplements.

Authors:  Martin J J Ronis; Kim B Pedersen; James Watt
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-10-06       Impact factor: 13.820

6.  A Retrospective Study of Clinical Effects of Powdered Caffeine Exposures Reported to Three US Poison Control Centers.

Authors:  Gillian A Beauchamp; Amberly R Johnson; Barbara I Crouch; Matthew Valento; B Zane Horowitz; Robert G Hendrickson
Journal:  J Med Toxicol       Date:  2016-04-04

7.  Detection of β-methylphenethylamine, a novel doping substance, by means of UPLC/MS/MS.

Authors:  Piotr Chołbiński; Mariola Wicka; Katarzyna Kowalczyk; Anna Jarek; Paweł Kaliszewski; Andrzej Pokrywka; Ewa Bulska; Dorota Kwiatkowska
Journal:  Anal Bioanal Chem       Date:  2014-03-16       Impact factor: 4.142

8.  Effects of controlled doses of Oxyelite Pro on physical performance in rats.

Authors:  Paulo Vinicios Camuzi Zovico; Victor Magalhães Curty; Marcos André Soares Leal; Eduardo Frizzera Meira; Daniel Ventura Dias; Lívia Carla de Melo Rodrigues; Silvana Dos Santos Meyrelles; Edilamar Menezes De Oliveira; Paula Frizera Vassallo; Valério Garrone Barauna
Journal:  Nutr Metab (Lond)       Date:  2016-12-06       Impact factor: 4.169

9.  Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products.

Authors:  Manuela Pellegrinia; Maria Concetta Rotolo; Francesco Paolo Busardò; Roberta Pacifici; Simona Pichini
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

10.  Amphetamine Abuse Related Acute Myocardial Infarction.

Authors:  Archana Sinha; O'Dene Lewis; Rajan Kumar; Sri Lakshmi Hyndavi Yeruva; Bryan H Curry
Journal:  Case Rep Cardiol       Date:  2016-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.